NICE is unable to make a recommendation on ciltacabtagene autoleucel (Carvykti) for treating relapsed or refractory multiple myeloma in adults. This is because Janssen withdrew its evidence submission for the appraisal. We will review this decision if the company decides to make a submission....

Fulltext

El Mieloma Múltiple es un tipo de neoplasia hematológica maligna incurable en la actualidad, que se caracteriza por la afección y multiplicación sin control de células plasmáticas en la médula ósea con su consecuente secreción de una proteína monoclonal y síntomas como anemia, hipercalcemia, f...

Fulltext

This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications....

Fulltext